Kuwayama Yasuaki

Change in visual acuity and associated risk factors after trabeculectomy with adjunctive mitomycin C.

Visual acuity was significantly reduced after MMC trabeculectomy in 5 years, and we identified several risk factors associated with this complication.

Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory.

Many glaucoma patients feel anxiety. The STAI-State is correlated with the VR-QOL and anxiety in glaucoma patients, making it useful for understanding the anxiety present in glaucoma patients.

Frequencies of 4 Distinct Patterns of Glaucomatous Disc Appearance and Their Clinical Associations in Japanese Population-based Studies.

The FG type occurs most frequently in Japanese POAG followed by the GE type.

Evaluation of Quality of Life in Japanese Glaucoma Patients and its Relationship With Visual Function.

Minimum threshold values of the 4 pericentral test points on the temporal side are useful for the assessment of VR-QOL.

One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.

Fifty-two week administration of 0.4% ripasudil revealed IOP-lowering effects and an acceptable safety profile when administered as monotherapy or as additive therapy, in patients with open-angle glaucoma or OHT.

Fornix-based Trabeculectomy With Mitomycin C Using the Horizontal Conjunctival Suture Technique.

The horizontal suture technique is an easily applied, less time-consuming technique that gives excellent bleb morphology with few complications in the long term.

Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.

These clinical trials found additive IOP-lowering effects of ripasudil from placebo at trough and peak levels in combination with timolol and at peak level in combination with latanoprost.

Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.

Ripasudil is a promising new topical medication to lower IOP for at least 7 hr after instillations in patients with POAG or OHT.